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Abstract 
 
Introduction: Medicines have made an appreciable contribution to improving health. However, even 
high income countries are struggling to fund new premium-priced medicines. This will grow 
necessitating the development of new models to optimise their use.  Objective: Review case histories 
among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, 
use these to develop exemplar models and outline their implications. Challenges and proposed 
models: A number of issues and challenges have been identified including the limited innovation level 
of new medicines alongside increasing requested prices for their reimbursement especially for 
oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and 
post-launch including critical drug evaluation and multi-criteria models for valuing medicines for 
orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed 
models which involve all key stakeholder groups are critical for the sustainability of healthcare 
systems or enhancing universal access. The models should help stimulate debate as well as restore 
trust between key stakeholder groups. 
 
Introduction 
 
Medicines have made an appreciable contribution to improving the health of patients and their 
survival (1-3). However, we are now seeing even high income countries struggling to fund new 
premium-priced medicines including new therapies to treat patients with cancer (4-9). Unless these 
problems are addressed, the number of struggling countries will grow driven by factors including 
changing demographics, increasing prevalence of non-communicable diseases (NCDs), rising patient 
expectations and the continued launch of new premium priced technologies  (10-20). New medicines  
increasingly include novel biological drugs (21), often priced at between US$100,000 - US$400,000 
(Euro74,000 ± 296,000) per patient per course or year (8, 10, 18, 22, 23). The challenges of funding 
new premium priced medicines are augmented by lobbying, marketing and other strategies among 
pharmaceutical companies, including influencing guidelines to accelerate the uptake of new 
medicines (24-32), despite the imposition of multi-million dollar fines (33-36). 
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Challenges to be addressed include adequately dealing with demands for premium prices for new 
medicines with often limited health gain versus current standards including those for cancer and 
orphan diseases (23, 37-39).  Funding new effective treatments for patients with hepatitis C virus 
(HCV) is a also growing concern given its prevalence and  requested prices for new treatments (6, 14, 
40). In some cases, concerns arise with patient safety when new medicines are used in a wider and 
less well-defined population than those enrolled into Phase III clinical trials (41). This was seen with 
the TNF alpha inhibitors when treating patients with immune diseases including rheumatoid arthritis 
as well as dabigatran in the prevention of stroke in patients with atrial fibrillation (41, 42). There has 
also been a lack of quality indicators for new medicines to optimise their prescribing (43). These 
various issues undermine  the continued provision of equitable and comprehensive healthcare in 
Europe as well as the potential for  universal healthcare coverage in countries striving for this (43, 44). 
This has resulted in several initiatives across countries to address this. Initiatives include the 
development of new models to optimise the managed entry of new medicines, instigating of registries 
to monitor the effectiveness and/ or safety of new medicines in routine clinical care, capped budgets, 
exploring the potential for differential pricing for new medicines as well as the development of 
multicriteria decision matrices for valuing new orphan medicinal products (OMPs).  
 
Consequently, the principal objective of this paper is to review ongoing and planned activities among 
health authorities to address these challenges  to provide future guidance. This will primarily be a 
descriptive review of case histories based on the considerable experience of the co-authors.  Whilst 
this review is mainly aimed at medium high and high income countries, the models and other 
suggested activities are highly relevant to low and middle income countries as they tackle even 
tougher challenges with providing access to important new medicines and limited studies to date to 
guide their activities (45).   
 
We recognise that health authorities must also seek ways to release additional resources to fund new 
valued premium priced medicines and increased drug volumes. Activities involve generic medicines 
(46-48), including ways to obtain low prices for good quality generics as well as increase their 
utilisation versus originators and patented (single-sourced) products in a class (48-52) They also 
involve appraising medicines and other technologies that should be discontinued (53-56) as well as 
potentially reviewing funding for the off-label use of medicines where there is robust evidence that 
they can act as alternatives to patented medicines, e.g. replacing the use of ranibizumab with  
bevacizumab to treat age-related macular degeneration (57-59). However, these activities are outside 
the scope of this paper. 
 
Current challenges in optimising the use of new medicines 
 
The challenges will be presented under two broad themes. These are: (A) valuing new medicines 
including disease areas where there are concerns with the budget impact; (B) Case histories of 
medicines where there are concerns with their effectiveness, safety or both. 
 
A) Valuing new medicines 
 
i) General 
 
Only a small number of new medicines can be classified as innovative. Prescrire, a critical 
independent drug information journal, believed only 2% of new medicines or new indications for 
existing medicines in France were innovative and/ or offered a real therapeutic advantage over 
existing treatments despite the hype (Table 1). Most new medicines or new indications were seen as 
possibly helpful or similar to existing treatments (38).  
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Table 1 ± Percentage ratings by the independent drug information journal Prescrire of the level of 
innovation of new medicines and new indications introduced in France between 2006 to 2011 (38) 
 
Prescrire ratings/ criteria 2006 2007 2008 2009 2010 2011 
Total number of new medicines/ new 
indications 
135 141 120 104 97 92 
Innovative medicine/ real therapeutic advance 1% 2% 0% 0% 1% 0% 
Offers an advantage over current standards 6% 10% 5% 3% 3% 3% 
Possibly helpful, minimal or no clinical 
advantage compared to existing standard 
treatments 
74% 75% 68% 73% 73% 72% 
Others including not seen as acceptable, 
including safety concerns, and judgement 
reserved due to for instance insufficient data 
from clinical trials 
19% 13% 27% 24% 23% 25% 
 
There were similar findings in other countries. Of the 217 approvals by the Australian Therapeutic 
Goods Administration between 2005 and 2007, only seven were rated as important therapeutic 
innovations (60). In Belgium, only 67 of 824 new medicine applications submitted to the authorities for 
reimbursement considerations between 2002 and 2004 claimed added therapeutic value, of which 
only half were eventually granted added therapeutic value by the Belgium authorities (61). Finally, 
since the mid-1990s, independent reviews have concluded that approximately 85-90% of all new 
medicines provide few or no clinical advantages for patients versus existing standards (37, 62).  
 
The pharmaceutical industry relies heaYLO\RQLQFUHPHQWDOLQQRYDWLRQVZKLFKFDQEHFDOOHGµPH-WRR¶
drugs, to sustain their profits (63). It is argued that since incremental innovations can be medically 
beneficial and should be encouraged (63). However, this will increasingly depend on requested prices 
given increasing pressure on resources (18, 39, 64). In addition, this will depend on available 
evidence with concerns with assessing the level of innovation of new medicines where only a placebo 
is used as the comparator (65, 66). This is leading to recommendations for more comparative data as 
well as longer term outcome rather than surrogate data to consolidate assessments of the value of 
new medicines (67). 
 
The low level of innovation of most new medicines is leading to a more critical assessment of their 
value. This will continue. 
 
ii) New treatments for cancer  
 
Prices of new cancer medicines have increased  up to ten-fold during the past 10 years, with prices 
likely to continue rising as most new cancer drugs are launched for targeted indications, with 
manufacturers typically seeking orphan status with associated high prices (19, 68, 69).  This is a 
concern with expenditure on oncology expected WRUHDFKRYHU86ELOOLRQ¼ELOOLRQLQ and 
US$173 billion in 2020XSIURP86WRELOOLRQLQ¼- ¼ELOOLRQ, limited correlation 
between resources spent on cancer care and mortality rates (69, 70), and new medicines to treat 
patients with cancer typically costing between US$6,000 to US$ 10,000 ¼± 7,500) per month, 
often with little relationship between reimbursed prices and associated health benefit (18, 22, 69), 
e.g.:  
x Of the 12 drugs approved by the FDA in the US for various cancer indications in 2012, 9 were 
priced at more than US10,000 per month with only 3 prolonging survival, two of them by less than 
2 months (39) 
x In renal cell cancer, 7 targeted therapies were approved in the US between 2005 and 2012. 
These include sunitinib (2006), everolimus (2009), pazopanib (2009) and axitinib (2012). All 
improved median progression-free survival (PFS) in the range of 3 to 6 months. However, this 
was associated with minimal or no improvement on overall survival times, at a cost of US$70,000 
to US$140,000 ¼WR annually (39). 
 
A different challenge is seen with trastuzumab emtansine (KADCYLA), which is an antibody±drug 
conjugate combining trastuzumab with the maytansinoid emtansine, a potent microtubule-disrupting 
agent (71, 72). Trastuzumab emtansine has an estimated incremental cost/ QALY up to GB£185,600 
5 
 
¼235,000) due to a median increased survival of 5.8 months compared with standard treatment in 
HER2 positive patients with metastatic breast cancer no longer responding to the combination of 
trastuzumab and a taxane (8), and a cost of GB£90,000 ¼per course (8, 73, 74). Other 
authorities though have calculated lower cost/ QALYs depending on the choice of comparator (73). In 
any event, this is considerably higher than trastuzumab alone even considering estimated costs of 
US$60 ± 90 million (GB$36 ± 55 million) for the development of new (successful) medicines (18, 22, 
75), although other authors have quoted higher figures (76). Development costs may be lower than 
this for trastuzumab emtansine as this builds on an existing technology.  
 
Challenges arise if pharmaceutical companies subsequently use the cost/ QALY for trastuzumab 
emtansine if reimbursed as a basis for future submissions. Media reports indicate the manufacturer 
may be putting pressure on European countries to reimburse trastuzumab emtansine at these prices 
by playing them against  each other (77). There are also challenges to health authority budgets  with 
annual peak sales for trastuzumab emtansine estimated at US$2 billion to US$5 billion ¼ELOOLRQWR
¼ELllion) (78). This builds on global sales of trastuzumab alone at CHIF6079 million (GB£ 
3985million, Euro5050million) in  2013 up from CHIF 5889 million in 2012 (79). Health authorities are 
aware that the prices of oral small molecules can be as low as 2% to 4% of originator prices (80-82), 
although cost-of-goods will be higher for biological products. In addition, they are aware 
pharmaceutical companies do spend appreciable monies on their marketing activities (28, 83). 
Consequently, it is likely health authorities will increasingly challenging companies on their pricing 
strategies for new oncology treatments as resource pressures grow (22). This will result in new cancer 
medicines increasingly being grouped with other new medicines for reimbursement considerations. 
 
ii) New treatments for patients with hepatitis C virus (HCV) 
 
As mentioned, funding new effective treatments for patients with HCV is a growing concern with more 
than150 to 185 million people worldwide believed to be infected with chronic HCV, high cure rates 
with second generation directly acting antivirals (DAAs) and associated costs (6, 14, 84, 85). For 
instance in Malaysia, the prevalence of HCV is estimated at 1.5% of the population (86). The primary 
goal of treatment is to cure the infection, defined as a sustained virological response (SVR) (14, 40, 
87).  Previous treatments have included pegylated interferon and ribavirin and more recently 
bocepravir and telapravir, first generation DAAs (6, 14). However particularly pegylated interferons 
and ribavirin caused serious side-effects in more than 80% of patients, resulting in less than 50% of 
patients completing the treatment course (6). Cure rates of up to 95% are now seen with second 
generation DAAs, sofosbuvir and semiprevir, providing shorter treatment courses as well as reducing  
side effects compared with current treatments (6, 14, 40, 87). Sofosbuvir combined with ledipasvir 
(HARVONI) has also achieved high cure rates with almost universal viral clearance after 8 weeks 
without the need for either pegylated interferons or ribavirin (84, 85). 
 
However a 12 week course for sofosbuvir costs GB£ WR¼± 90,470) depending 
on the genotype (40). The much quoted price in the USA is US$1000 per pill equating to US$84,000 
¼IRUDVWDQGDUGFRXUVHKRZHYHUSULFHVSHUFRXrse can be as low as US$900 in Egypt and 
some developing countries (6, 88). Prices for sofosbuvir combined with ledipasvir are similar at 
US$94,500 per 12 week course (89, 90). Sales of sofosbuvir were US$2.8billion in the third quarter of 
2014, with sales of the second generation DAAs likely to appreciably increase with further launches 
(90). It has been calculated that if all 3 million people estimated to be infected with HCV in the USA 
are treated with second generation DAAs, annual spending on all prescription drugs will double from 
approximately $300 billion currently  (6, 88). Uptake is likely to be more gradual than this though and 
expenditure is likely to fall in the future with an appreciable number of patients cured with the second 
generation DAAs. 
 
iii) Funding new treatments for patients with diabetes 
 
Funding new premium priced medicines for patients with diabetes is also a growing concern among 
health authorities with estimates that by 2035 nearly 600 million people world-wide will have diabetes 
and almost 500 million at risk for the disease (91). Diabetes, including its complications, is one of 
leading causes of deaths worldwide (16, 91). Morbidity and mortality rates alongside health care 
spending, which currently accounts for approximately 11% of total healthcare spending (91), will grow 
if not addressed (90). The increasing prevalence of patients with type 2 diabetes (T2DM) has 
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stimulated research into new treatment options, which now include Į-glucosidase inhibitors, 
thiazolidinediones, meglitinides, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl 
peptidase inhibitors (DPPs or gliptins), sodium glucose co-transporter 2 (SGLT2) inhibitors and 
modified insulins (92, 93). As a result, global expenditure on medicines to treat patients with diabetes 
is estimated to reach US$48 to 53bn in 2016, with similar figures in 2017 (94, 95). 
 
However, most guidelines recommend prescribing newer treatments as third line following metformin 
monotherapy and combinations of established agents, due to a lack of comparative effectiveness 
studies and given their considerably higher costs (96) . There are also concerns that the gliptins, e.g. 
saxagliptin, sitagliptin and vildagliptin, appear to have no proven efficacy on the complications of 
diabetes whilst adverse effects include immune disorders, pancreatitis and hypersensitivity reactions 
(97).  Given the rising prevalence of patients with T2DM and the lack of robust data for the newer anti-
diabetic medications, health authorities need to monitor their use and effectiveness in reducing micro- 
and macro-vascular complications. It is also important that health authorities focus on preventative 
measures that have been shown to be effective in controlling T2DM and related complications (98, 
99). 
  
iv) New medicines for orphan diseases 
 
New orphan medicinal products (OMPs), some costing RYHU¼PLOOLRQSHUSDWLHQWSHU\HDU(20, 23, 
100), are also putting pressure on healthcare budgets, especially with some OMPs achieving 
blockbuster status (9, 100, 101). This increases the debate whether pharmaceutical companies 
should also consider social good alongside financial returns (20), and whether health authorities 
should be more critical when assessing the value of new OMPs. 
 
Expenditure on OMPs has been influenced by few marketing authorisation and reimbursement 
hurdles at requested prices (9, 102-107). However, this is changing with managed entry agreements 
increasingly needed for successful reimbursement. The use of multi-criteria decision matrices is also 
in development among European health authorities and other key stakeholder groups to address 
increasing concerns as well as reduce the evidence gap between countries for successful 
reimbursement (102, 108). These concerns are illustrated by the considerable controversy 
surrounding the reimbursement for enzyme replacement therapy for the symptomatic treatment of 
Fabry disease in the Netherlands at an incremental cost/ quality adjusted life-\HDURI¼PLOOLRQ(9). 
The reimbursement body argued that continued reimbursement  would reduce available resources for 
other, more cost effective, health technologies (9). A similarl situation was seen with alglucosidase 
alfa to treat Pompe¶V disease at an estimated cost/ QALY  of ¼±0.9 million for the classic form up 
WR¼PLOOLRQ4$/<IRUWKHQRQ-classic form  (9). The draft advice was leaked prior to its official 
release, leading to vocal opposition and pressure on the Ministry of Health to ignore the advice (9).  
 
A similar situation was seen in Lithuania with galsulfase (Naglazyme®) for the management of 
patients with for mucopolysaccharidosis VI. Whilst long-term treatment has been shown in studies to 
reduce progression and morbidity (109), currently funding all 10 patients in Lithuania with this 
condition would represent 17% of the total in-patient budget for medicines and medical aids and 3% 
of total reimbursed ambulatory care pharmaceutical expenditure. Pressure is being placed on the 
Ministry of Health and Health Insurance Fund to reimburse galsulfase for these patients despite 
concerns with its value.     
 
A different challenge is seen with ivacaftor, which is a new medicine for the treatment of 5% of 
patients with cystic fibrosis (CF) who carry the genetic mutation G551D (20). Ivacaftor was granted 
reimbursement in the UK at a cost/ QALY, after an agreed discount, RI4$/<¼WR
£1.077million/QALY ¼PLOOLRQ(104). ,YDFDIWRU¶Vpricing strategy of $294,000 ¼)/ patient/ 
year for life was based on perceived similar prices for other treatments for rare diseases (110). Its use 
is likely to grow in patients with other genotypes as well as with potential combination with lumacaftor 
(111-113). The decision by the NHS Commissioning Board to recommend funding put pressure on 
Scotland, which resulted in funding despite advice from the HTA agency not to recommend use (104, 
111, 114). This also caused a domino effect on Wales and Northern Ireland. In Australia,  the 
manufacturer and patient groups are putting pressure on the government to fund ivacaftor, especially 
following a proposed managed entry agreement (115). If funded, this could result in companies 
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seeking funding for their new OMPs at similar cost/ QALYs, exacerbating future challenges across 
countries.  
 
B) Case histories where concerns with the effectiveness, safety or both of new medicines 
 
i) Transplantation therapies (Brazil) 
 
Brazilian guidelines recommend that the principal medication used to prevent rejection following renal 
transplantation is ciclosporin, with concomitant azathioprine and corticosteroids (116). Alternatively, 
ciclosporin can be replaced by tacrolimus and azathioprine may be replaced by mycophenolate 
mofetil or sirolimus. However, it is currently unknown whether there are differences in renal graft and 
recipient survival rates between the different regimens especially with limited follow-up in Phase III 
trials. Studies have reported increased initial survival among transplant patients receiving a 
tacrolimus-based therapeutic regimen when compared with those receiving ciclosporin-based 
regimens. However, long term studies have not uniformly confirmed this apparent advantage of a 
tacrolimus-anchored immunosuppression regimen. 
 
This information gap was narrowed by researchers in Minas Gerais, Brazil, performing an historical 
cohort case controlled study among 5686 patients who underwent renal transplant and received either 
ciclosporin or tacrolimus.  A higher risk of treatment failure was associated with tacrolimus (HR 1.38, 
95% CI 1.14 to 1.67), higher patient age at transplantation, donor types, median time of dialysis prior 
to transplantation, and diabetes as a cause of chronic renal failure (CRF) (116). After adjusting the 
model for possible confounding factors such as sex, age, graft origin, prior time of dialysis, and cause 
of CRF, the authors concluded that the risk of treatment failure of patients receiving tacrolimus was 
1.38 times that of patients receiving ciclosporin -  thereby justifying the continued recommendation of 
ciclosporin as first line treatment in these patients (116). 
 
ii) Dabigatran to prevent stroke and systemic embolism/clot formation in adult patients with non-
valvular atrial fibrillation (pre- to post-launch) 
 
Concerns with the safety and the potential budget impact of dabigatran when prescribed in more 
elderly co-morbid populations that those recruited into Phase III clinical trials (13, 41, 117). These 
concerns resulted in a number of professional bodies and health authorities initiating extensive pre- 
and peri-launch programmes, some of which are listed in Table A1 (Appendix). These tactics were 
also driven by the manufacturer failing to share relevant information about the potential benefits of 
monitoring anticoagulant activity, and adjusting doses with physicians, to reduce possible major 
bleeds post-launch (118, 119). 
 
iii) TNF alpha inhibitors in patients with rheumatoid arthritis 
 
A range of studies have been undertaken across countries to assess the effectiveness and long-term 
safety of the TNF (tumour necrosis factor) alpha inhibitors in patients with rheumatoid arthritis due to 
concerns with their safety and value at launch . Two examples of healthcare initiated programmes are 
included in Table 2. 
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Table 2- Healthcare post-launch programmes to study the effectiveness and safety of patients with 
rheumatoid arthritis treated with biological medicines 
 
Country Study and findings 
Italy(120) x The objective of the study was to evaluate 4-year retention rates of TNF-Į inhibitors 
adalimumab, etanercept, and infliximab among patients with long standing 
rheumatoid arthritis (RA) using the GISEA registry 
x Persistence over the 4 years was lower than 50%, with etanercept having the best 
retention rate 
x The main positive predictor of patient adherence was the concomitant use of 
methotrexate 
x The study also provided evidence that the management of patients with RA in the 
clinic may well be different from RCTs 
Sweden ARTIS 
(Anti Rheumatic 
Therapies in 
Sweden) (42, 121) 
x A study group of all rheumatology clinics in Sweden with high patient involvement in 
data catchment showed: 
o RA patients treated with biological drugs are not at increased risk of 
invasive melanoma  
o RA patients selected for TNF alpha inhibitor treatment are not at 
increased overall risk for cancer but have a 50% increased relative risk 
of invasive melanoma 
x Given the small increase in absolute risk, the authors concluded these findings do 
not shift the overall risk-benefit balance of anti-TNF alpha inhibitors in clinical 
practice, but might do so in patients at high risk of melanoma for other reasons  
 
A retrospective review of the use of anti TNF alpha inhibitors in patients in Austria with ankylosing 
spondylitis showed that whilst patients were treated most often with adalimumab, patients on 
etanercept showed the lowest switching rate and the longest 1- and 2-year retention rate (122).  
 
iv)  Effectiveness and cost-effectiveness of new medicines post launch (US) 
 
Drug utilisation studies are increasingly being undertaken in the USA to assess the cost-effectiveness 
of new medicines in clinical practice as part of formulary decisions. The introduction of health care 
reforms, and a significant focus on specialty pipeline medicines and their increased identification 
(123), is reinforcing the focus on the appropriate care of these patients.  
 
Models are being created that look at comparator products in therapeutic class combined with their 
costs, including pharmacy and medical costs, to identify differences in the clinical outcomes of the 
different therapies and their associated costs. This includes comparing new medicines with 
established standards and determining the most appropriate clinical end points. The models 
developed by managed care organisations typically focus on overall cost and event reduction 
including reduced hospitalization, emergency room visits, and per member per month (PMPM) costs.  
 
These approaches also provide insight into potential models for different member populations to 
improve care in the future within finite resources with the increase in accountable care organisations. 
 
Proposed models and advice to optimise the utilisation of new medicines  
 
i) Proposed model (general) 
 
These examples illustrate the need for a comprehensive model to optimise the clinical uptake and 
safety monitoring of new medicines as well as their costs post-launch.  This approach requires closer 
collaboration between researchers, policy makers and pharmaceutical companies as well as the 
development of critical drug evaluation skills among all key stakeholder groups and a defined role for 
experts and professional groups such as clinical pharmacologists, clinical pharmacists and health 
economists, working with health authorities in the development of robust treatment guidance pre- and 
post-launch of new medicines (124-128). This close collaboration between pharmacotherapeutic 
experts, clinical pharmacologists and other key stakeholder groups is seen as essential to maintain 
high standards of evaluations and recommendations.  
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The proposed model starts pre-launch (Figure 1). Pre-launch activities incorporate horizon scanning 
and potential budget impact analysis as well as starting to develop potential quality indicators for new 
medicines. Peri-launch activities include critical drug evaluation, cross-discipline guideline 
development as well as pricing and reimbursement deliberations (41, 43, 129-134). It is envisaged 
health authorities will become more critical in their reimbursement deliberations for new medicines 
given concerns with the limited health gain of most new medicines alongside ever increasing 
requested prices and their associated budget impact. Post-launch activities include assessing the 
effectiveness, safety and value of new medicines in clinical practice especially if patients in clinical 
practice will be older and more co-morbid than those enrolled into Phase III studies (135, 136). They 
also include assessing prescribing against agreed guidance and in line with any developed quality 
indicators, and subsequently instigating additional activities including educational initiatives if needed. 
 
Figure 1 ± Proposed model to optimise the managed entry of new medicines (adapted from 
references (41, 137) 
 
 
 Horizon scanning 
activities
 Assessing the budget 
impact of new medicines 
based on likely patient 
numbers through 
assessing likely target 
patient populations as 
well as potential 
modifications to patient 
care including new 
laboratory tests
 Start developing patient 
registries 
 Start developing clinical 
guidelines/ product 
guidance based on critical 
drug evaluations. 
Similarly for new quality 
indicators (QIs)
 Potentially instigate 
dialogue with all key 
stakeholder groups
 Pricing and 
reimbursement 
negotiations for new 
medicines 
 Evaluate proposed 
managed entry 
agreements as well as 
potential prices to stay 
within agreed budgets
 Finalise patient registries, 
guidelines and any QIs for 
new medicines
 Instigate educational 
activities with all key 
stakeholder groups based 
on unbiased information 
developed in collaboration 
with DTCs, 
pharmacotherapeutic
experts and clinical 
pharmacologists. There 
must be easy access to 
information
 Follow-up of the 
effectiveness and safety 
of new medicines in 
clinical practice through 
electronic health records/ 
registries
 Continue with educational 
activities in collaboration 
with DTCs,  
pharmacotherapeutic
experts and clinical 
pharmacologists to 
counter-act potentially 
biased information from 
pharmaceutical 
companies
 Evaluate adherence to 
any agreed prescribing 
guidance or restrictions, 
as well as against any 
agreed QIs
 Instigate additional 
demand-side measures if 
needed 
Pre-launch 
activities
Post-launch 
activities
Peri-launch 
activities
 
 
Table A2 expands on potential activities pre- to post-launch (Figure 1). New Zealand, Poland and 
Turkey provide guidance on potential ways to keep expenditure on new medicines within agreed limits 
(below). 
 
Quality indicators (Figure 1) are increasingly used as a method to help achieve safe and quality 
clinical care, cost-effective therapy, for professional learning, remuneration, accreditation and financial 
incentives. A substantial number focus on drug therapy; however, few have addressed the 
introduction of new medicines (43). A suggested framework and indicator testing protocol among 
health authority personnel and other interested groups for subsequent introduction into clinical 
practice has recently been developed (43). 
 
ii) Early dialogue between key stakeholder groups in the development of new innovative medicines 
(Pre-launch) 
 
There is an increasing need for all key stakeholder groups to interact earlier in the development 
process for new innovative medicines especially as there are no specific guidelines that combine the 
requirements of both regulators and payers when assessing the efficacy, safety and potential value of 
new medicines (128).  However, this is beginning to change (67). 
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As mentioned, Phase III clinical trials are typically conducted under ideal and highly controlled 
conditions to seek high internal validity (41, 138). However, this may lead to substantial differences 
from their subsequent use in clinical practice (13, 138). In addition, there can be concerns with 
surrogate markers, e.g. progression free survival in solid tumours may not always translate into 
LPSURYHGFOLQLFDOO\UHOHYDQWRUµKDUG¶RXWFRPHV(5, 39).  
 
Consequently, interaction between key stakeholder groups during clinical development to discuss 
early-stage scientific reimbursement advice should assist with development plans, especially where 
there are areas of concern including issues of clinically relevant comparators as well as clinical and 
patient-relevant outcomes (67). This should also help reduce duplication between the requirements of 
the different government groups as well as build trust between the various groups. This is already 
happening in Australia and Europe (128, 139), building on initiatives to try and harmonise information 
requirements between payers and HTA bodies across continents (67). 
 
iii) Capped budgets and other mechanisms to potentially optimise utilisation and funding for new 
medicines (Peri- and post-launch)  
 
The reimbursement body of New Zealand (PHARMAC) operates within a fixed budget prioritising 
funding for new medicines on strict criteria including the potential for funding their use in defined sub-
populations where their value is greatest (Box 1), balancing funding for the new premium priced 
medicines against potentially better investments with existing medicines (140-142). There is also the 
potential for cross-company deals, with PHARMAC agreeing to fund a new medicine at an agreed 
price in a defined patient population in exchange for the manufacturer lowering the cost of their other 
listed medicines (140). This in turn may result in a lower reference prices for particular classes as a 
whole further conserving resources.  
 
Box 1 ± New Zealand¶VNH\GHFLVLRQPDNLQJFULWHULD for new medicines (adapted from references 
(140, 142-144) 
 
x Health needs of all the eligible population with a particular focus on the health needs of Maori and 
Pacific peoples 
x Availability and suitability of existing medicines, treatment devices, and related products 
x Clinical benefits and risks of the new medicine in all/ sub-populations 
x Cost effectiveness of meeting health needs by funding the new medicine in all/ sub-populations 
rather than using other publicly funded health and disability support services. There is no set cost/ 
QALY threshold. However, between the 1998 and 2007, individual new investments made by 
PHARMAC varied between 25 QALYs gained for every NZ$1 million (Euro623,000) saved by the 
NZ health sector and less than 5 QALYs gained for every NZ $1 million spent. Expressed as 
costs per QALYs, investments varied between saving NZ$40,000 per QALY gained (- 
Euro25,000) and spending over NZ$+200,000 per QALY (Euro125,000) 
x Budgetary impact of any changes to the medicine schedule from reimbursing the new medicine at 
agreed prices in agreed populations 
x Direct cost to health service users 
x New Zealand goverQPHQW¶VSULRULWLHVIRUKHDOWKIXQGLQJ 
x Such other criteria as PHARMAC thinks suitable after appropriate consultation 
 
A recent comparative analysis of the approval and funding of new drugs showed that only 59 (43%) of 
the 136 medicines listed in the Australian PBS between 2000 and 2009 were listed in the New 
Zealand reimbursement l schedule, with listings occurring on average just under three years after 
Australia (145). This may at least be in part due to  the reimbursement body in New Zealandoperating 
within a fixed budget, prioritising new medicines against each other and against access to all 
medicines (141, 142).  
 
In Turkey, the Turkish Medicine and Medical Devices Agency is responsible for key areas including 
licensing, pricing, quality control, pharmacovigilance and clinical drug trials. A reference pricing 
system has been in existence since 2004 based on the lowest ex-factory price in either Greece, 
France, Italy, Portugal or Spain as well as the country in which the pharmaceutical is being 
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manufactured. The Social Security Institution is responsible for reimbursement decisions. Companies 
must provide evidence demonstrating cost-effectiveness of their new medicine versus current 
standards to be considered for reimbursement, and are expected to give a discount from ex-factory 
prices except where retail prices are less than 3.56 TL ¼SHUGLVSHQVHGLWHP. At the end of 2009 
and 2011, price cuts and discounts were instigated by the Government to keep pharmaceutical 
expenditure under control. Between 2010 and 2012, a global budget was also implemented to further 
control pharmaceutical expenditure. This led to additional price cuts for both new and established 
medicines.  
 
In Poland, the National Health Fund drug budget cannot exceed 17% of the total yearly budget for all 
sectors. This has resulted in one reimbursement list which is divided into three categories (Box 2), 
with an economic analysis (typically either a cost-effectiveness analysis or cost-utility analysis) 
required to assess the potential reimbursement for new expensive medicines alongside a budget 
impact analysis (146). The economic assessments are undertaken by the HTA agency (AHTAPol) 
(Box 2), which was established in 2005 in Poland by the Ministry of Health, which became law in 2009 
(146).  
 
Box 2 ± Categories for the reimbursement list as well as the activities of AHTAPol (37, 41, 146-150) 
 
A) Three categories for the reimbursement list 
x An ambulatory care reimbursement list where patient co-payments can vary between 0%, 30%, 
50% as well as a lump sum of ¼SHUSUHVFULSWLRQ 
x Healthcare programme lists for costly medicines for use in hospitals with strict inclusion and 
exclusion criteria and no patient co-payments 
x +RVSLWDO¶VFKHPRWKHUDS\OLVW 
 
B) Influence/ impact 
x Among the 151 drug technologies appraised between 2007 and 2009 in Poland, 34 medicines 
were appraised and reimbursed, 117 were appraised and not reimbursed and 29 were 
reimbursed and not appraised. Even when new medicines are reimbursed in Poland, there can be 
restrictions, e.g.14 of medicines had major restrictions, 11 had minor restrictions and 5 without 
restrictions 
x The most common restriction was recommendations for prescribing at a lower price and 
restrictions to specific sub-populations. Restricting reimbursement of premium-priced medicines is 
also seen in other European countries to contain costs 
x Common reasons for rejection included insufficient clinical data, poor efficacy or safety, or an 
unacceptable cost-effectiveness ratio 
 
x A recent analysis undertaken by the HTA agency (AHTAPol) comparing the outcomes of their 
recommendations for new antineoplastic medicines issued in 2013 with the reimbursement list 
officially published by the Ministry of Health in January 2014, found  that only 6 of 26 (30%) 
oncology medicines were included in the reimbursement list, with all of them being positive 
recommendations by AHTAPol  
x Recommendations relating to reassessments, off-label use of medicines or individual treatment 
agreements were excluded from this analysis 
x No new oncology medicine with a negative recommendation appeared on the reimbursement list 
x Consequently, it appears that new medicines with negative recommendations will probably not be 
accepted for reimbursement from public sources in Poland, endorsing the approaches in Poland 
to enhance the efficient use of resources allocated for new medicines 
 
iv) Models for differential pricing strategies for new medicines (per- and post-launch) 
 
There have been a number of proposals and examples for differential (or tiered) pricing arrangements 
for new medicines and new vaccines, especially among lower income and developing countries 
where affordability is an issue (151). This is seen in the differential pricing for sofosbuvir between 
Egypt and the United Kingdom(6). More recently, the European Pharmaceutical Industry Federation 
(EFPIA) proposed tiered pricing strategies for countries struggling to fund new medicines provided 
certain pre-conditions are met (Box 3) 
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Box 3 ± Suggested pre-conditions from the industry federation (EFPIA) to enhance access to new 
medicines through differential pricing (152) 
 
x Any scheme should be the result of bilateral voluntary arrangements at a national level that 
protect the confidentiality of any net pricing arrangement 
x International reference pricing schemes should be founded on best practices to ensure 
consistency 
x Member States should take the necessary steps to ensure that medicines specifically priced 
for patient groups who would not otherwise be able to afford them are delivered to those 
patients and are not otherwise diverted 
 
However, such strategies decrease transparency and increase information asymmetry between 
pharmaceutical companies and health authorities with production and pricing information typically 
kept in confidence by the manufacturers (153). There is also currently no systematic global framework 
on potential pricing approaches for middle-income countries, which can result in protracted and 
damaging negotiations pitting manufacturers against public health institutions, including health 
authorities, country-by-country and commodity-by-commodity (153). Such arrangements also amount 
to more developed countries subsidizing medicines for less developed countries.  
 
Initiatives to increase affordable access to medicines, including low and middle- income countries, 
advocated in the literature include countries encouraging robust generic competition as well as taking 
advantage of public health intellectual property flexibilities to enhance competition generally (151, 
154).  This is because manufacturers do not typically have strong incentives to re-evaluate tier prices 
in the absence of competition (151). It is recognised though that tiered pricing may be a potential 
option to meet short-term needs in special cases where affordability to new essential medicines is a 
major issue. These include situations when market volumes are small and there is currently no 
competition. However, we recommend steps should be taken to ensure affordability and availability in 
the long term as well as stimulating competition (151).  
 
v) Initiatives to improve the interface management for drug therapies 
 
Post launch activities increasingly include improving prescribing cohesion between hospital and 
ambulatory care, with the majority of new biological medicines typically initiated by specialist 
physicians in hospitals. 7KLVLVFDOOHGµLQWHUIDFHPDQDJHPHQW¶DQGLVLQFUHDVLQJO\LQVWLgated across 
countries starting with active drugs and therapeutic committees (DTCs) in hospitals (126) (Table 3). 
Improved interface management can increase the quality of prescribing as well as reduce costs in 
ambulatory care especially if the prices of new medicines are heavily distorted in hospital through the 
considerable discounts offered by pharmaceutical companies to increase their prescribing (126, 155).  
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Table 3 ± Strategies to improve interface management (13, 81, 82, 125, 126, 156-158) 
 
Country Strategy 
Scotland x Mutual list of recommended medicines for primary and hospital care has been 
present in Scotland in the various regions for over 20 years, with high physician 
adherence rates to the recommendations 
x There is active involvement of both ambulatory care and hospital physicians in the 
regional Drug and Therapeutics Committees (DTCs) and in developing joint 
UHFRPPHQGDWLRQVDQGJXLGHOLQHVWRHQKDQFHDGKHUHQFHLHQR³FDUWHEODQFKH´IRU
specialists, with the formulary guidance applying equally across all sectors. Non-
formulary prescribing is permitted but only if it can be justified 
x Prescribing guidance and guidelines are based on evidence based assessments of 
the safety and efficacy of medicines with costs an additional factor  
x Encouraging good communication and development of clinical networks between 
the sectors as well as the development of 
electronic information systems as well as educational activities including academic 
detailing  
Spain (Catalonia) x DTCs in the region have developed and instigated prescribing indicators for new 
and existing medicines to improve patient care across all sectors as well as cost-
effective prescribing 
x The Catalonian electronic systems permit sharing of clinical data between sectors. 
This includes the ability of GPs to debate and challenge specialist recommendations 
where this is seen to contradict advice from the health authority 
Sweden 
(Stockholm 
Healthcare Region) 
x There has been a long tradition of selecting and recommending evidence-based 
medicines for common diseases in ambulatory care in the Stockholm Metropolitan 
Healthcare Region (leading to WKHµ:LVH/LVW¶GLUHFWHGE\DKLJKGHJUHHRI
involvement of prescribing physicians as well as respected pharmacotherapeutic 
experts and clinical pharmacologists with scientific training through joint 
DSSRLQWPHQWVZLWKLQKHDOWKFDUHDQGXQLYHUVLW\VHWWLQJVLQGHYHORSLQJWKHµ:LVH/LVW¶
This contains approximately 200 medicines, with a separate list for hospitals 
x The long term strategy has been to advocate thaW³HDFKUHFRPPHQGHGPHGLFLQH
VKRXOGEHRIKLJKYDOXHWRWKHSDWLHQW´ 
x Respected specialists, working jointly with clinical pharmacologists, pharmacists and 
general practitioners in over 20 expert groups, suggest which medicines should be 
selected and included in the µ:LVH/ist¶. Suggestions are subsequently debated by 
WKH'7&IRUSRWHQWLDOLQFOXVLRQLQWKHQHZµ:LVH/LVW¶ 
x The recommended medicines are subsequently collated, widely communicated and 
disseminated each year in different versions for healthcare staff and the public  
x High physician DGKHUHQFHWRWKLVYROXQWDU\µ:LVH/LVW¶ when prescribing,   reaching 
87% of all prescriptions in primary care in 2009, has been achieved through a 
number of factors. These include physician trust in those developing the prescribing 
guidance, robust handling of  conflicts of interest,  involvement of prescribers and 
drug experts in its development, active dissemination strategies, regular yearly 
updates as well as regular monitoring of physician prescribing against prescribing 
guidance 
 
vi) Valuing new orphan drugs ± Transparent Value Framework (TVF) 
 
The Transparent Value Framework (TVF) was developed as part of the European project on  
coordinated access to orphan medicinal products (MoCA) under the platform Access to Medicines  
(101, 159). Its development arose as a result of the ongoing challenges posed by pricing and funding 
of the new orphan medicinal products (OMPs) (108), conceived as an aid to the MoCA process by 
providing a framework for discussions on clinical effectiveness, recognizing that it would be more 
efficient to avoid duplication of effort for appraising OMPs among the member states.  
 
In particular, it was envisioned that these discussions would lead to an agreement among 
stakeholders, including payers and pharmaceutical companies, on the therapeutic value of a new 
OMP, subsequent to discussions between and among key stakeholders on which value 
(high/medium/low) to assign to which attribute (Unmet need/Degree of net benefit, Response rate, 
Degree of certainty). Consequently, the development of the TVF through the collaborative process 
should improve consistency in decision making between European countries, reducing evidence gaps 
that currently exist. Consequently, the first step to address this critically important issue. 
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The TVF (Table 4) consists of four elements of value coupled with the extent to which each criterion is 
met as a basis for price negotiations. ,WLVUHFRJQL]HGWKDWWKHIUDPHZRUNLVµLQGLFDWLYHQRQ-
prescriptive and non-ELQGLQJ¶DFNQRZOHGJLQJWKDWUHLPEXUVHPHQWGHFLVLRQVIRUQHZ203VDUHWKH
responsibility of individual EU Member States (108).  
 
Table 4 - The Transparent Value Framework adapted from (108) 
 
Criterion Low Degree Medium Degree High Degree 
Available Alternatives / Unmet Need 
(defined as the degree to which the new 
OMP addresses the unmet need over 
existing therapies). Where no 
pharmaceutical alternatives exist, other 
non-pharmaceutical treatment can be 
used as the benchmark 
Alternatives 
available 
 
New medicine 
does not 
address unmet 
need 
Alternatives 
available but 
major unmet need 
still exist 
 
No alternatives 
exist except 
supportive care, 
Major unmet 
need is met 
(Relative) Effectiveness, Degree of Net 
Benefit relative to alternatives 
including no treatment. Net benefit 
includes for instance the degree of clinical 
improvement with the new OMP, 
including improved Quality of Life (QoL) 
versus current treatments, measured 
against the potential side effects  from the 
new OMP 
Incremental Major Curative 
Response Rate (will vary depending on 
which measure, including surrogate 
markers and time frames are used as well 
as the available clinical data) 
<30% 30-60% >60% 
Degree of Certainty (defined as the 
certainty of the claim made by the market 
authorization holder for their new OMP) 
Promising but 
not well-
documented 
Plausible Unequivocal 
 
There is ongoing research to assess the utility of the TVF in practice and make subsequent 
recommendations to aid future decision making in this critically important area. This may lead to an 
adaptation of the TVF in the future. In the meantime, potential strategies could include health 
authorities reviewing the criteria for granting orphan status as proposed recently by Garattini (160). 
 
Discussion  
 
The case histories demonstrate that health authorities are using a number of approaches to optimise 
the managed entry of new medicines starting pre-launch (Figure1). This also includes valuing new 
OMPs (Table 4) as well as looking at considerations such as capping budgets for the future 
sustainability of healthcare systems. This is becoming crucial given increasing prices for new 
medicines, especially biological medicines, and their potential budget impact. The Pharmaceutical 
industry is a global industry and often successful market access techniques are replicated across 
countries. Health authorities must recognise this and develop, test and share approaches among 
themselves to sustain their future. This resulted in the proposed model to optimise the managed entry 
of new medicines (Figure 1), which can be used across all countries including developing and 
emerging countries challenged with both new expensive medicines to treat prevalent infectious 
diseases as well as  increasingly  non-communicable diseases (14-16). Instigating this model will 
require (clinical) pharmacologists, clinical pharmacists, health economists, biostatisticians and other 
healthcare professionals to improve the critical drug evaluation skills of physicians starting pre-launch 
and continuing post-launch (13, 126, 161). This approach will help counter-act the influence of 
pharmaceutical companies where this is a concern (28, 33, 83). The development of these models will 
also require healthcare systems to invest in independent drug expert competence to ensure a critical 
mass of available experts and staff to critically evaluate the potential role and value of new costly 
medicines as well as undertake additional educational activities. Health systems will also need to 
invest in continuous professional development to improve the knowledge among prescribers and 
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healthcare staff on how to optimally use medicines including new medicines to balance against the 
marketing activities of pharmaceutical companies (28, 29, 126, 162-164). Such initiatives will require 
close collaboration between organisations and establish key roles for DTCs as well as the 
involvement of therapeutic experts and academics. The use of such personnel has worked well in the 
Stockholm Healthcare Region with developing the µ:LVH/LVW¶DQGDFKLHYLQJKLJKDGKHUHQFHUDWHV
(Table 5) (125, 126).. Development of these models (Figure 1) together with improvements in critical 
drug evaluation skills, including appropriate outcome measures, should also reduce some of the 
inconsistencies that exists in Europe when authorities assess the relative value of mew medicines 
(165).  
 
National patient association groups also need to work alongside health authorities pre- and peri-
launch to help fully assess potential patient populations for new medicines, especially if there are 
safety concerns and where the potential budget impact in all proposed patients will affect the 
sustainability of healthcare systems (13, 166). Such groups may also be employed to develop and 
disseminate factual information for patients peri- to post-launch (41), thereby helping communicate  
the rationale behind funding decisions and enhancing the focus on existing evidence-based systems  
(167).  
 
Finally, it is recognised that maintaining agencies for designing, conducting and evaluating ongoing 
and future policies and strategies is disproportionately more burdensome for smaller countries than 
for developed countries with a large base of contributors. On the other hand, some medicines are not 
made available in smaller markets, due to economic considerations, exacerbating the difficulties these 
countries face when providing healthcare (168). The cross-border healthcare directive across Europe 
is also putting pressure on countries to ensure continuity of treatment after patient movement. Ideally, 
this will require similar quality of health technology assessments for new medicines . Cooperation to 
evaluate and debate these key issues is ongoing starting pre-launch (67). Organisations involved 
include EuroScan (133, 169), the  Piperska group (who provided the majority of co-authors for this 
paper (10, 129)), EUnetHTA , which is working on EU-wide collaboration producing product 
evaluations and the MEDEV group representing the payers. Co-operation is demonstrated by the 
proposed model to improve the managed entry of new medicines (Figure 1) as well as the initiation of 
MoCA to develop potential frameworks to value new OMPs (Table 4). Such activities will grow given 
ever increasing pressure on resources.  
 
Conclusion 
 
We hope we have demonstrated why new models are critical to improve the managed entry of new 
medicines. Without these, countries will increasingly struggle to fund new premium priced medicines 
as well as maintain equitable and comprehensive healthcare or achieve universal access. The various 
models and their implications were discussed to provide exemplars to countries given ever-increasing 
pressure on resources, and should help restore trust between all key stakeholder groups, which has 
been diminished in recent years.  
 
Expert commentary and five year review 
 
All countries, even high income countries, will struggle to fund new premium priced medicines  in the 
future driven by a number of factors. These include the launch of new biological drugs at ever 
increasing prices, including those for cancer and orphan diseases, often with limited health gain 
versus current standards. The launch of new medicines in diseases of high prevalence, including 
patients with Type 2 diabetes and HCV, is putting additional pressure on healthcare systems which 
needs addressing. This has necessitated the development of new models. This includes greater 
scrutiny over the value of new medicines at requested prices as well as restrictions to sub-populations 
where they provide the greatest value. It also increasingly includes potentially capping pharmaceutical 
expenditure. These developments are likely to apply to all new medicines including those for cancer 
and orphan diseases especially as a number of these products have already achieved blockbuster 
status. As a result, decrease the difference in evidence gaps that currently exists between countries 
for reimbursement considerations. However, this must not be at the expense of diminishing research 
into identified priority disease areas. These developments will require (clinical) pharmacologists, 
clinical pharmacists, health economists, biostatisticians and other healthcare professionals to improve 
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the critical drug evaluation skills of physicians starting pre-launch and continuing post-launch. It will 
also require health systems to invest in continuous professional development. 
 
Key issues 
 
x Medicines have made an appreciable contribution to improving healthcare. However, even high 
income countries are now struggling to fund new premium priced medicines 
x The number of struggling countries will grow unless addressed driven by factors including 
changing demographics and the continual launch of new premium priced medicines often with 
limited health gain versus current standards 
x High prices are a particular issue for new medicines for cancer and orphan diseases. This 
includes trastuzumab emtasine and ivacaftor 
x Another challenge facing health authorities are the launch of new effective but high priced 
medicines for hepatits C as well as new premium priced medicines for patients with Type 2 
diabetes given the prevalence of both diseases 
x Professional bodies including physicians and health authorities have also instigated measures 
including educational activities, prescribing restrictions and registries where they have been 
concerned with the effectiveness and/ or safety of new medicines in clinical practice especially 
when the population is older with greater co-morbidities than patients enrolled into Phase III 
clinical trials 
x Health authorities have instigated a number of measures to address these challenges including 
developing new models to optimise the managed entry of new medicines. These start pre-launch 
with horizon scanning and budgeting. Peri-launch activities include the critical evaluation of the 
role, value and place in therapy of new medicines with post launch activities including evaluating 
prescribing against guidelines and quality indicators as well as addressing concerns with interface 
management where these exist. Other activities to optimise pharmaceutical budgets include 
expenditure caps with trade-offs between prices of new and established medicines as well as the 
development of multi-criteria matrices to standardise the valuation of new medicines for orphan 
diseases  
x Clinical pharmacologists, clinical pharmacists, health economists, biostatisticians and other 
healthcare professionals will need to play a key role with improving the critical drug evaluation 
skills of physicians to optimise the use of new medicines. Health systems will also need to invest 
in continuous professional development for their long term sustainability 
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Supplementary Appendix ± Are new models needed to optimize the utilisation of new 
medicines to sustain healthcare systems? 
 
Table A1 ± Case histories of health authority activities across countries pre- to post-launch of 
dabigatran 
 
Country Details of activities undertaken 
Ireland (1-4) x The National Centre for Pharmacoeconomics (NCPE) stated in August 2011 that 
µGDELJDWUDQetexilate could be considered cost effective treatment for the 
SUHYHQWLRQRIVWURNHLQSDWLHQWVZLWK$)¶+RZHYHUWKHUHZHUHFRQFHUQVwith 
some of the clinical data, model assumptions and budget implications leading to 
recommendations to reduce the price  
x Following this, the manufacturer reduced its price leading to NCPE now 
considering dabigatran cost effective  
x Dabigatran prescribing was investigated post launch - 5012 patients for >35 
days. A high proportion of patients were found to be concurrently receiving 
medicines which may increase the risk of bleeding; 36% receiving dabigatran for 
>35 days were found to be prescribed at least one ³FDXWLRQ´ drug (defined in the 
Summary of Product Characteristics ) 
x This analysis followed various publications in Ireland which had expressed 
concern regarding the potential for inappropriate prescribing of dabigatran in 
clinical practice 
x Following the analysis, a letter was sent by the authorities to all physicians in 
Ireland reminding them of the appropriate prescribing of new oral anti-
coagulants (NOACs). The National Medicines Management Programme has 
also published concise prescribing advice summaries regarding the NOACs as 
part of ongoing efforts to reduce the potential for prescribing errors. 
Malaysia (5, 6) x The Malaysian Adverse Drug Reaction Advisory Committee (MADRAC) had 
receive 58 reports and 83 adverse reactions regarding dabigatran from 2009 till 
March 2013 
x Based on the high number of cases reported, a guidance on the monitoring of 
dabigatran usage in public and private facilities was developed. This comprised 
details of suggested usage, workflow and a checklist in the prescribing and 
GLVSHQVLQJRIGDELJDWUDQHPSKDVL]LQJRQWKHLPSRUWDQFHRIPRQLWRULQJSDWLHQW¶V
renal status. Detailed programmes for initiating and maintaining dabigatran 
therapy was also included in the guidance  
x As part of the initiative, dabigatran can only be initiated by consultants in public 
health institutions. In addition, it is mandatory that all patients prescribed 
dabigatran be counselled by pharmacist at the point of dispensing  
x The National Drug Safety Monitoring Centre has also issued advice (Reaksi ± 
Drug Safety News) on the prescribing of dabigatran  
New Zealand (1, 7, 8) x A regional study did not ascertain any inappropriate prescribing of dabigatran 
according WRSDWLHQWV¶UHQDOIXQFWLRQ, which reflected extensive local educational 
initiatives by the Best Practice Advisory Centre (BPAC) pre- and peri-launch as 
well as initiatives by local prescribers (BPAC is a national programme but there 
are regional initiatives. In some localities prescribers did not adhere to the 
recommendations resulting in unnecessary bleeding and deaths) 
x This contrasted with a high number of adverse events (ADRs) reported to the 
national New Zealand Centre for Adverse Drug Reaction Monitoring following 
the launch of dabigatran. However, increased publicity on ADRs and increasing 
knowledge about dabigatran, especially renal function, has resulted in a 
reduction in reported ADRs in recent months   
Slovenia (1) The prescribing of dabigatran was restricted post-launch to reduce potential 
bleeding. The restrictions include: 
o Only reimbursed if initiated by an internist or neurologist and prescribed 
according to agreed indications with patients typically followed in a tertiary 
or secondary anticoagulation centre  
o Anticoagulation centres have to report once yearly regarding the number of 
patients experiencing minor and major bleeding, thromboembolic events, as 
well as any deaths from bleeding or thromboembolism with dabigatran 
 
Analysis of utilisation patterns post launch would suggest the restrictions are being 
followed in practice to reduce the potential for bleeding  
2 
 
Sweden (Stockholm 
Healthcare Region) 
(2) 
Extensive activities were undertaken by the Drugs and Therapeutics Committee in 
the Stockholm Healthcare Region to limit potential ADRs with dabigatran post 
launch. These included: 
x Appreciable number of pre-launch meetings and training sessions with all 
physician groups 
x Key messages broadcasted both to the public and to prescribers through 
websites of the DTC as well as the Swedish Medical Journal 
x Production of educational folders regarding dabigatran, slide kits, published 
articles, and data on the Janus website as well as widely distributing published 
information to patients 
x Developing a laboratory method to monitor dabigatran in plasma 
It is believed these activities limited the extent of any excessive bleeding with 
dabigatran in the Stockholm Healthcare region post launch 
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Table A2 ± Summary of potential activities for new medicines amongst key stakeholder groups  
 
Activity Summary of activities/ suggestions to optimise the utilisation of new medicines 
Pre-launch 
activities(1, 
2, 9-21) 
x Horizon scanning activities of new medicines: 
o DHILQHGDV³identifying new medicines or new uses of existing medicines that are 
expected to receive marketing authorisation from the Regulatory Authority in the 
near future and estimating their potential impact on patient care´, typically instigated 
up to three years before likely launch dates.  
o Generally incorporate a limited number of Phase II study results as well as possibly 
interim or final Phase III results, balancing timeliness with accuracy. Prioritisation of 
medicines for evaluation typically includes their likely health benefit versus current 
standards and their potential budget impact. This can also include potential adverse 
reactions if there are safety concerns with new medicines in wider co-morbid 
populations than those included in Phase III trials, e.g. dabigatran. Table A3 
contains the current filtering process for new anti-cancer medicines in Austria 
x Forecasting the potential influence of the new medicine on the healthcare organization, 
identification of needs for continued medical education as well as their potential budget 
impact. One example of forecasting combining a number of factors to determine potential 
drug expenditures is the model developed in Sweden (Stockholm Healthcare Region). 
Development of a structured process for the introduction of new medicines and protocols to 
monitor prescribing post-launch including developing quality indicators  
x Preparing physicians on how to handle new medicines through targeted educational 
activities, e.g. dabigatran 
x Appraising the possibility of following-up prescribing through registries and Electronic Health 
Records 
x Early dialogue between pharmaceutical companies and health authorities including key 
comparator and outcome data for Phase II/ III clinical trials.  
During the pre-launch phase, as well as during the other phases, it is critical to ensure the 
involvement of independent pharmacotherapeutic experts, clinical pharmacologists and 
pharmacists as part of a professionally guided organization, e.g. Drug and Therapeutic 
Committees (DTCs) or similar organizations in the three phases of the model. This will ensure 
access to competence regarding basic and clinical sciences, and well as build trust around 
conflict of interest considerations when recommending and using new medicines. Advice on how 
to design and carry out critical drug evaluations have been published  
Peri-launch 
activities 
(2, 9, 22-
36) 
x Different approaches are used across countries to value new medicines. In some European 
countries, agreed reimbursed prices are based on the perceived level of health gain versus 
current standards broken down by established criteria, e.g. Austria, France and Germany. In 
others, decisions are based on economic criteria such as the incremental cost/ QALYs 
(ICERs) versus current standards (with or without suggested ICER threshold levels) 
x Pricing and reimbursement considerations increasingly include appraising risk sharing 
arrangements or managed entry agreements (MEAs) given ever increasing requested prices 
and resource concerns. MEAs include financial based schemes such as price: volume 
agreements and price capping schemes as well as outcome based schemes including 
payment by result schemes and coverage with evidence schemes. However, the lack of 
publications discussing MEAs and their outcome is a concern among health authorities 
across countries 
x 'HWHUPLQLQJWKH³EHVWSRLQWRIFDUH´LHZKHUHDQGE\ZKRPWKHGHFLVLRQLVPDGHWRLQLWLDWH
the prescribing of new medicines , and where prescribing should be initiated and carried on, 
e.g. teaching hospitals or other specialized centres, primary care physicians or other facilities 
with a degree of specialisation in between. 
Post-
launch 
activities 
(1, 2, 11, 
18, 28, 30, 
31, 37-40) 
x Monitoring prescribing against agreed restrictions, prescribing guidance or quality targets 
issued by national medical organizations and DTCs. This should reduce potential adverse 
drug reactions that could arise from inappropriate prescribing of new medicines 
x Targeting prescribing to sub-populations is increasingly possible with the growing use of 
sophisticated information technology systems, including e-prescribing and electronic health 
records. The growth in pharmacogenomics will help  
x Assessing the effectiveness and safety of new medicines in routine clinical practice using 
patient registries, databases and electronic health records combined with a clear strategy for 
their integration into clinical practice with associated follow-on research  
x Any drug utilisation studies undertaken should be integrated into clinical research agendas, 
agreed peri-launch between universities and healthcare organizations and national 
stakeholders involved in the Rational Use of Medicines 
x Since most new innovative medicines are launched worldwide, monitoring should ideally 
enable the concentration/ combining of worldwide datasets to achieve maximum validity 
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Table A3 ± Filtering process and prioritisation of new anti-cancer medicines in Austria (14) 
 
x Criteria for filtration 
o New (early post marketing) 
o Emerging (Phase II or III Clinical Trials) 
o Use in adults including solid malignancies, leukaemia and lymphomas 
o Likelihood of extended indications beyond the initial submitted indication 
x Prioritisation criteria 
o Number of patients eligible for the cancer medicine under consideration 
o Intended use of the new medicine, i.e. as add-on to existing regimes or as a 
replacement to existing regimes 
o EsWLPDWHGLPSDFWRQSDWLHQWV¶RXWFRPHV 
o Estimated budget impact 
o Potential for off-label use to increase the budget impact 
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